Back to Journals » International Medical Case Reports Journal » Volume 7

A successful case of dose reduction in etizolam dependence using fine granules: a case report

Authors Nishii S, Hori H, Kishimoto T, Nakamura J

Received 1 May 2014

Accepted for publication 16 June 2014

Published 21 August 2014 Volume 2014:7 Pages 121—122

DOI https://doi.org/10.2147/IMCRJ.S67103

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4


Shigeki Nishii,1 Hikaru Hori,1 Toshifumi Kishimoto,2 Jun Nakamura1

1Department of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan; 2Department of Psychiatry, Nara Medical University, Shijocho, Kashihara, Nara, Japan

Abstract: The prevalence of benzodiazepine consumption in Japan is one of the highest worldwide. Etizolam is the most abused drug of the benzodiazepine class. The treatment of benzodiazepine dependence is difficult. We report a case of successful dosage reduction in a 24-year-old female patient with etizolam dependence. She was diagnosed with etizolam dependence at the age of 22 years old. We proposed a benzodiazepine dependence treatment that involved replacing etizolam with a long-acting benzodiazepine class drug in conjunction with a long-term weaning plan. However, the patient refused the treatment and insisted that reducing the number of tablets would increase her anxiety. After providing a detailed explanation and receiving consent from the patient, a treatment regimen consisting of fine granules of etizolam mixed with lactose granules was begun with the aim of reducing the percentage of etizolam at a rate of 0.3 mg/week. The treatment of etizolam dependence in this patient was successful. This treatment strategy may be an effective option for patients who are difficult to treat with conventional methods, or who have anxiety regarding the reduction of the amount of the drug itself.

Keywords: benzodiazepine, Japan, dependence, etizolam

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]